Division of Transfusion Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Am J Clin Pathol. 2012 Jul;138(1):12-9. doi: 10.1309/AJCPLRIOJP55JAYT.
In 2008, the World Health Organization (WHO) revised the classification system for myeloproliferative neoplasms (MPNs). MPNs include chronic myelogenous leukemia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, and several other disorders. The newer classification system incorporates mutations discovered in the JAK2 and MPL genes. The importance of understanding the role of mutations in JAK2, MPL, and other genes that have been discovered in MPNs is highlighted by the change in the 2008 WHO MPN classification system. Moreover, the development of highly specific inhibitors of JAK2 further stresses the importance of molecular testing in MPN diagnosis and prognosis.
2008 年，世界卫生组织（WHO）修订了骨髓增殖性肿瘤（MPN）的分类系统。MPN 包括慢性粒细胞白血病、特发性血小板增多症、真性红细胞增多症、原发性骨髓纤维化症以及其他几种疾病。新的分类系统纳入了在 JAK2 和 MPL 基因中发现的突变。2008 年 WHO MPN 分类系统的改变凸显了了解 JAK2、MPL 和其他在 MPN 中发现的基因突变的作用的重要性。此外，JAK2 高度特异性抑制剂的开发进一步强调了分子检测在 MPN 诊断和预后中的重要性。
